MCID: RFR010
MIFTS: 48

Refractory Anemia

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Refractory Anemia

MalaCards integrated aliases for Refractory Anemia:

Name: Refractory Anemia 55
Refractory Anemia, Without Ringed Sideroblasts, Without Excess Blasts 69
Refractory Anemias 69
Anemia Refractory 51

Characteristics:

Orphanet epidemiological data:

55
refractory anemia
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 55 ORPHA98826
MESH via Orphanet 42 D000753
UMLS via Orphanet 70 C0002893
ICD10 via Orphanet 33 D46.7

Summaries for Refractory Anemia

MalaCards based summary : Refractory Anemia, also known as refractory anemia, without ringed sideroblasts, without excess blasts, is related to refractory anemia with excess blasts and chromosome 5q deletion syndrome. An important gene associated with Refractory Anemia is TET2 (Tet Methylcytosine Dioxygenase 2), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Iron and Deferasirox have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are cellular and hematopoietic system

Related Diseases for Refractory Anemia

Diseases related to Refractory Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 refractory anemia with excess blasts 34.0 ASXL1 TET2
2 chromosome 5q deletion syndrome 29.9 EPO TET2
3 myelodysplastic syndrome 29.8 ASXL1 EPO IL3 JAK2 MPL RUNX1
4 leukemia 29.7 JAK2 MPL RUNX1
5 anemia, sideroblastic, 1 29.5 ALAS2 TET2
6 myeloid leukemia 29.4 IL3 RUNX1 TET2
7 myeloproliferative neoplasm 29.4 JAK2 MPL TET2
8 myelodysplastic myeloproliferative cancer 29.4 ASXL1 JAK2 TET2
9 chronic myelomonocytic leukemia 29.3 ASXL1 JAK2 RUNX1 TET2
10 pancytopenia 29.1 EPO MPL
11 acute leukemia 29.1 IL3 JAK2 RUNX1
12 splenomegaly 29.1 EPO JAK2 MPL
13 thrombocytosis 29.0 EPO IL3 JAK2 MPL TET2
14 megakaryocytic leukemia 28.7 IL3 JAK2 RUNX1
15 aplastic anemia 28.6 ASXL1 EPO IL3 MPL TET2
16 deficiency anemia 28.5 ALAS2 EPO IL3
17 leukemia, acute myeloid 28.1 ASXL1 IL3 JAK2 MPL RUNX1 TET2
18 polycythemia 27.8 EPO IL3 JAK2 MPL TET2
19 essential thrombocythemia 27.7 ASXL1 EPO IL3 JAK2 MPL TET2
20 myelofibrosis 27.6 ASXL1 EPO IL3 JAK2 MPL TET2
21 polycythemia vera 27.4 ASXL1 EPO IL3 JAK2 MPL TET2
22 refractory anemia with excess blasts in transformation 12.2
23 refractory anemia with excess blasts type 2 12.2
24 refractory anemia with excess blasts type 1 12.0
25 pyridoxine-refractory autosomal recessive sideroblastic anemia 11.5
26 aregenerative anemia 11.3
27 anemia, sideroblastic, 3, pyridoxine-refractory 11.0
28 acquired idiopathic sideroblastic anemia 11.0
29 anemia, sideroblastic, 2, pyridoxine-refractory 11.0
30 folic acid deficiency anemia 10.2 EPO TET2
31 pyridoxine-responsive sideroblastic anemia 10.2 ALAS2 TET2
32 acquired polycythemia 10.2 EPO JAK2
33 systemic mastocytosis 10.2 JAK2 TET2
34 acute erythroid leukemia 10.2 EPO JAK2
35 atransferrinemia 10.1 ALAS2 TET2
36 thrombocytopenia-absent radius syndrome 10.1 JAK2 MPL
37 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.1
38 blood coagulation disease 10.1 JAK2 MPL
39 core binding factor acute myeloid leukemia 10.0 JAK2 RUNX1
40 budd-chiari syndrome 10.0 JAK2 MPL
41 microcytic anemia 10.0 ALAS2 EPO
42 pdgfrb-associated chronic eosinophilic leukemia 9.9
43 amegakaryocytic thrombocytopenia, congenital 9.9 IL3 MPL
44 anemia of prematurity 9.8 EPO IL3
45 atypical chronic myeloid leukemia 9.8 ASXL1 JAK2 RUNX1
46 juvenile myelomonocytic leukemia 9.8 JAK2 RUNX1 TET2
47 lupus erythematosus 9.8
48 sideroblastic anemia 9.8
49 thymoma, familial 9.8
50 siderosis 9.8

Graphical network of the top 20 diseases related to Refractory Anemia:



Diseases related to Refractory Anemia

Symptoms & Phenotypes for Refractory Anemia

MGI Mouse Phenotypes related to Refractory Anemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.88 ASXL1 EPO JAK2 MPL RUNX1 TET2
2 hematopoietic system MP:0005397 9.87 ALAS2 ASXL1 EPO JAK2 MPL RUNX1
3 embryo MP:0005380 9.77 EPO JAK2 MPL RUNX1 ALAS2
4 immune system MP:0005387 9.73 ASXL1 EPO JAK2 MPL RUNX1 TET2
5 liver/biliary system MP:0005370 9.55 ASXL1 EPO JAK2 RUNX1 TET2
6 mortality/aging MP:0010768 9.5 ALAS2 ASXL1 EPO JAK2 MPL RUNX1
7 neoplasm MP:0002006 8.92 ASXL1 JAK2 RUNX1 TET2

Drugs & Therapeutics for Refractory Anemia

Drugs for Refractory Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
2
Deferasirox Approved, Investigational Phase 4,Phase 2 201530-41-8 5493381
3 Chelating Agents Phase 4,Phase 1,Phase 2
4 Iron Chelating Agents Phase 4,Phase 2
5
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
7
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
8
Daunorubicin Approved Phase 2, Phase 3, Phase 1 20830-81-3 30323
9
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
10
Idarubicin Approved Phase 2, Phase 3, Phase 1 58957-92-9 42890
11
Cytarabine Approved, Investigational Phase 2, Phase 3, Phase 1 147-94-4 6253
12
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
13
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
14
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
16 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
17
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
18
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
19
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
20
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
21
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
22
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
23 Magnesium citrate Approved Phase 3
24
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1 104987-11-3 445643 439492
25
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
26
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
27
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 460612 4053
28
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
29
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
30
Hydroxyurea Approved Phase 3 127-07-1 3657
31
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
32
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 657311 5754
33
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
34
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
35
Benzocaine Approved, Investigational Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
36
Thioguanine Approved Phase 3 154-42-7 2723601
37
Asparaginase Approved, Investigational Phase 3 9015-68-3
38
Aldesleukin Approved Phase 3,Phase 1,Phase 2 110942-02-4, 85898-30-2
39
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 6400441 383414
40
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 77-92-9 311
42
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
43 tannic acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
45
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538
46
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
47
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
48 Prednisolone acetate Phase 2, Phase 3, Phase 1
49 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
50 Analgesics Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 203)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
2 Bowel Preparation and Prokinetics in Capsule Endoscopy Unknown status NCT00275184 Phase 3 Senna;Citramag powder;Metoclopramide
3 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
4 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3 Darbepoetin alpha;Filgrastim
5 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
8 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
9 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
10 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
11 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
12 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Completed NCT00004208 Phase 3 ATG + CSA
13 Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes Completed NCT00003138 Phase 3
14 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
15 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
16 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
17 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
18 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
19 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
20 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
21 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
22 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
23 Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias Recruiting NCT02384122 Phase 2, Phase 3 Octreotide
24 G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Recruiting NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
25 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
26 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
27 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
28 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
29 Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes Unknown status NCT01129739 Phase 2
30 Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome Unknown status NCT00003123 Phase 2 amifostine trihydrate
31 Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00017550 Phase 2
32 Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
33 Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
34 Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome Unknown status NCT00513578 Phase 2
35 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
36 Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003681 Phase 2 amifostine trihydrate
37 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
38 Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
39 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML Completed NCT00854945 Phase 1, Phase 2 ON 01910.Na
40 A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome Completed NCT00001839 Phase 2 Antithymocyte globulin;Cyclosporine
41 Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies Completed NCT00208923 Phase 2 Busulfan, Cyclophosphamide and Fludarabine
42 Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
43 Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome Completed NCT00005598 Phase 2 amifostine trihydrate;azacitidine
44 Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant Completed NCT01012492 Phase 2 Abatacept
45 Thalidomide in Treating Patients With Myelodysplastic Syndrome Completed NCT00015990 Phase 2 thalidomide
46 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed NCT01165996 Phase 1, Phase 2 decitabine
47 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
48 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies Completed NCT01175785 Phase 2 fludarabine phosphate;cyclophosphamide;cyclosporine;mycophenolate mofetil
49 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed NCT00462605 Phase 2 entinostat;sargramostim
50 Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Completed NCT00003415 Phase 1, Phase 2 amifostine trihydrate;topotecan hydrochloride

Search NIH Clinical Center for Refractory Anemia

Genetic Tests for Refractory Anemia

Anatomical Context for Refractory Anemia

MalaCards organs/tissues related to Refractory Anemia:

38
Myeloid, Bone, Bone Marrow, T Cells, Kidney, Testes, Endothelial

Publications for Refractory Anemia

Articles related to Refractory Anemia:

(show top 50) (show all 402)
# Title Authors Year
1
Refractory anemia with ring sideroblasts and thrombocytosis. ( 28401094 )
2017
2
Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II). ( 28652792 )
2017
3
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. ( 28188970 )
2017
4
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis. ( 27301073 )
2016
5
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. ( 27558206 )
2016
6
Management of differentiation syndrome in an elderly patient with acute promyelocytic leukemia who subsequently developed refractory anemia with ring sideroblasts. ( 27073113 )
2016
7
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. ( 27479179 )
2016
8
Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations. ( 27994837 )
2016
9
Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). ( 27771989 )
2016
10
"Irony" of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. ( 27102761 )
2016
11
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). ( 26855506 )
2016
12
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. ( 27107658 )
2016
13
Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q). ( 28092889 )
2016
14
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. ( 26874914 )
2016
15
Refractory anemia in human immunodeficiency virus: Expect the unexpected. ( 28217621 )
2016
16
Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. ( 27104191 )
2016
17
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. ( 26967822 )
2016
18
A Case of Refractory Anemia with Excess Blast-2 with Sole Trisomy 13. ( 26299091 )
2015
19
Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation. ( 25963624 )
2015
20
Severe Refractory Anemia in Primary Intestinal Lymphangiectasia. A Case Report. ( 26405709 )
2015
21
Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. ( 25926061 )
2015
22
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). ( 26400023 )
2015
23
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T). ( 25899435 )
2015
24
Biosimilar epoetin I+ is as effective as originator epoetin-I+ plus liposomal iron (SideralAr), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach. ( 26171179 )
2015
25
Refractory anemia in systemic sclerosis: myelodisplastic syndrome. ( 27708945 )
2015
26
Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia. ( 26457287 )
2015
27
An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report. ( 25621045 )
2015
28
Deferasirox in a refractory anemia after other treatment options: case report and literature review. ( 26185629 )
2015
29
Abnormalities in the T Cell Receptor VI' Repertoire and Foxp3 Expression in Refractory Anemia with Ringed Sideroblasts. ( 26154600 )
2015
30
Metastatic Choriocarcinoma of the Small Intestine Presenting as Refractory Anemia and Melena. ( 26157939 )
2015
31
Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association. ( 26133721 )
2015
32
Dramatic improvement of refractory anemia caused by mechanical hemolysis in a patient with hypertrophic obstructive cardiomyopathy using dual-chamber pacing. ( 26336568 )
2015
33
Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. ( 25955609 )
2015
34
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. ( 25527566 )
2015
35
Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts. ( 25709892 )
2015
36
Myeloid Sarcoma of the Bladder in the Setting of Refractory Anemia with Excess Blasts-2 (RAEB-2). ( 26665895 )
2015
37
Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. ( 24958999 )
2014
38
Histopathological evaluation of the bone marrow in refractory anemia with ring sideroblasts and thrombocytosis associated to the JAK2-V617F mutation. ( 24624040 )
2014
39
A yet unreported der(11)t(6;11)(p21;q21) included in a complex karyotype of a refractory anemia with ring sideroblasts and poor prognosis. ( 24439112 )
2014
40
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. ( 24476767 )
2014
41
Refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T). ( 24575445 )
2014
42
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. ( 22929973 )
2013
43
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( 23515411 )
2013
44
Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy. ( 24371768 )
2013
45
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. ( 23065512 )
2013
46
Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the FAB classification. ( 23897263 )
2013
47
Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases. ( 24399021 )
2013
48
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. ( 23070040 )
2013
49
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis. ( 23252419 )
2013
50
Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. ( 23566303 )
2013

Variations for Refractory Anemia

Expression for Refractory Anemia

Search GEO for disease gene expression data for Refractory Anemia.

Pathways for Refractory Anemia

GO Terms for Refractory Anemia

Biological processes related to Refractory Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 covalent chromatin modification GO:0016569 9.58 ASXL1 JAK2 TET2
2 cytokine-mediated signaling pathway GO:0019221 9.5 IL3 JAK2 MPL
3 hemopoiesis GO:0030097 9.43 ASXL1 RUNX1
4 positive regulation of DNA replication GO:0045740 9.37 EPO IL3
5 regulation of cytokine-mediated signaling pathway GO:0001959 9.26 IL3 RUNX1
6 hemoglobin biosynthetic process GO:0042541 9.16 ALAS2 EPO
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.13 EPO IL3 JAK2
8 erythrocyte differentiation GO:0030218 8.8 ALAS2 EPO JAK2

Sources for Refractory Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....